<p>Hyderabad-based vaccine manufacturer Biological E has applied for Emergency Use Authorisation (EUA) for its Covid vaccine Corbevax for children in 5 to 12 age bracket, official sources said on Wednesday.</p>.<p>In February, the Biological E had received the EUA for Corbevax from India's drug regulator Drugs Controller General of India (DCGI) for the 12 to 18 age group.</p>.<p><a href="https://www.deccanherald.com/tag/coronavirus" target="_blank"><strong>CORONAVIRUS COVERAGE ONLY ON DH</strong></a></p>.<p>Corbevax is India's first indigenously developed Receptor Binding Domain (RBD) Protein sub-unit vaccine against Covid-19.</p>.<p>The RBD is a part of the spike protein of SARS-CoV-2. The virus uses the spike protein to attach itself to host cells.</p>.<p>The DCGI had also approved Corbevax for restricted use in emergency situation among adults on December 28, 2021. The Biological E received the approval for restricted use in an emergency situation in adolescents aged 12 to less than 18 years based on interim results of the ongoing phase II/III clinical study.</p>.<p>Corbevax is India's third indigenous Covid-19 vaccine after Covaxin and Zydus Cadila's ZyCoV-D vaccine.</p>.<p><strong>Check out latest coronavirus-related videos from <i data-stringify-type="italic">DH</i>:</strong></p>
<p>Hyderabad-based vaccine manufacturer Biological E has applied for Emergency Use Authorisation (EUA) for its Covid vaccine Corbevax for children in 5 to 12 age bracket, official sources said on Wednesday.</p>.<p>In February, the Biological E had received the EUA for Corbevax from India's drug regulator Drugs Controller General of India (DCGI) for the 12 to 18 age group.</p>.<p><a href="https://www.deccanherald.com/tag/coronavirus" target="_blank"><strong>CORONAVIRUS COVERAGE ONLY ON DH</strong></a></p>.<p>Corbevax is India's first indigenously developed Receptor Binding Domain (RBD) Protein sub-unit vaccine against Covid-19.</p>.<p>The RBD is a part of the spike protein of SARS-CoV-2. The virus uses the spike protein to attach itself to host cells.</p>.<p>The DCGI had also approved Corbevax for restricted use in emergency situation among adults on December 28, 2021. The Biological E received the approval for restricted use in an emergency situation in adolescents aged 12 to less than 18 years based on interim results of the ongoing phase II/III clinical study.</p>.<p>Corbevax is India's third indigenous Covid-19 vaccine after Covaxin and Zydus Cadila's ZyCoV-D vaccine.</p>.<p><strong>Check out latest coronavirus-related videos from <i data-stringify-type="italic">DH</i>:</strong></p>